Long-term Clinical Follow up After PCI for CTO
- Conditions
- Coronary Total Occlusion
- Registration Number
- NCT06544174
- Lead Sponsor
- University Hospital, Montpellier
- Brief Summary
The research aimed to evaluate the impact of a successful Percutaneous coronary intervention of chronic total occlusions (CTO-PCI) on long-term MACE (Major Cardiovascular Events), symptoms, survival, Left Ventricular Ejection Fraction (LVEF) and myocardial ischemia up-to-8-years follow-up.
- Detailed Description
With this observational and prospective study, this research aimed to evaluate the impact of a successful CTO-PCI on long-term MACE (Major Cardiovascular Events), symptoms, survival, LVEF and myocardial ischemia up-to-8-years follow-up.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 463
- 18 years or older
- who underwent at least one CTO procedure between 2025 and 2022 in Montpellier University Hospital
- symptomatic of reversible myocardial ischemia
- proof of myocardial viability
- refusal of the patient to participate to the study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Major cardiovascular events (MACE) Up to 8 years Incidence of composite of cardiac death, non-fatal myocardial infarction and new target vessel revascularization
- Secondary Outcome Measures
Name Time Method Restenosis Up to 8 years Incidence of Restenosis Defined as a greater than 50% diameter stenosis at follow-up angiogram of the first dilated total occlusion. Reocclusion was defined as recurrent total occlusion of the first dilated total occlusion.
Ischemic burden Up to 8 years Comparison between pre and post-CTO ischemic tests
Non combined MACE components Up to 8 years Incidence of Cardiac death, non-fatal myocardial infarction and new target vessel revascularization
LVEF Up to 8 years Percentage of Increase or decrease in LVEF after the CTO procedure compared with baseline LVEF
In-hospital events Up to one week Incidence of Procedural complications including death, periprocedural MI, coronary perforation, pericardial tamponade requiring drainage, local vascular complications, major bleeding, contrast induced nephropathy, stroke
Stent thrombosis Within 30 days after the procedure Incidence of stent thrombosis defined as any myocardial infarction with angiographic confirmation of in-stent thrombus or unexplained death
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
University Hospital
🇫🇷Montpellier, France
University Hospital🇫🇷Montpellier, France